Copper peptide is shorthand for GHK-Cu — the tripeptide-copper complex glycyl-L-histidyl-L-lysine bound to copper(II) — and the broader category of copper-containing peptides used in skincare and longevity products. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing, collagen and elastin synthesis, and anti-inflammatory effects.
2026 has been the year copper peptides crossed into mainstream consumer skincare. BoomRx launched a copper-peptide skincare line at the A4M Longevity SpringFest in April; Neurogan Health expanded with a 2% GHK-Cu topical body care backed by a 12-week clinical trial reporting 32.8% wrinkle-depth reduction and 20–30% improvement in skin firmness. Search interest in GHK-Cu has grown over 1,000% year-over-year per published trend data.
The regulatory split: topical GHK-Cu is a cosmetic ingredient, while injectable GHK-Cu sits in the FDA Category 2 reclassification queue alongside BPC-157 and others ahead of the July 23–24 PCAC meeting. Stories here cover product launches, clinical evidence, and the topical-vs-injectable distinction. See #ghk-cu, #anti-aging, and #skincare.
Neurogan Health expanded its product line with a topical 2% GHK-Cu copper peptide body care, supported by a 12-week clinical trial reporting 32.8% reduction in wrinkle depth and 20–30% improvement in skin firmness. The launch lands in a 2026 GHK-Cu market characterized by surging consumer interest — the peptide is the fastest-growing skincare ingredient by search volume, with patient interest spanning skin rejuvenation, hair loss, and systemic longevity. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing and collagen synthesis, and topical applications avoid the regulatory gray zone around the injectable formulation.
Pharmaceutical platform BoomRx debuted its copper peptide skincare line at the A4M Longevity SpringFest conference in West Palm Beach. The flagship product features Copper Tripeptide-1 (GHK-Cu), targeting med-spa and wellness practices already offering GLP-1, hormone, and hair loss treatments.
Dermatology Times Q&A explores advances in GHK-Cu delivery for skincare, discussing how the peptide complexes with copper in human plasma and new formulation approaches to improve topical efficacy.